Endurant CHevAr New Indication Trial: ENCHANT

Inclusion Criteria:

• Subject is ≥18 years old

• Subject is scheduled for primary treatment of the juxtarenal aortic aneurysm with ashort infrarenal neck (i.e. no revision subjects)

• Subject is able and willing to comply with the protocol and to adhere to thefollow-up requirements

• Subject has provided written informed consent

• Subject is an eligible candidate according to the currently available EndurantII/IIs instructions for use for ChEVAR

• Subject has a juxtarenal aortic aneurysm with a short infrarenal neck (definition ofjuxtarenal aortic aneurysm with a short infrarenal neck will be in accordance withcommercially available Endurant II/IIs instructions for use for ChEVAR).

Exclusion Criteria:

• Subject is participating in a concurrent study which may confound study results

• Subject has a life expectancy ≤ 2 year

• Subject has an aneurysm that is:

• Suprarenal or pararenal

• Isolated iliofemoral

• Mycotic

• Inflammatory

• Pseudoaneurysm

• Subject requires emergent aneurysm treatment, for example, trauma or rupture

• Subject has previously undergone surgical treatment for abdominal aortic aneurysm

• Subject is a female of childbearing potential in whom pregnancy cannot be excluded

• Subject has a known hypersensitivity or contraindication to anticoagulants,anti-platelets, or contrast media, which is not amenable to pre-treatment

• Subject has a creatinine level >2.0 mg/dl (or >176.8 μmol/L) and/or is on dialysis

• Subject has an active COVID-19 infection or relevant history of COVID-19. Relevanthistory of COVID-19 is defined as availability of a positive COVID-19 test withsequela or hospitalization for treatment of COVID-19. Subjects with a positiveCOVID-19 test who were asymptomatic or had mild symptoms should be excluded only ifthe positive test was less than 6 months prior to enrollment